Charles D. Ebert is Sr. VP & Research & Development at WATSON PHARMACEUTICALS INC (WPI). They have made 8 open-market trades across 2 companies since 2009, most recently 2013-11-06.
CIK 0001241752
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ACT | SELL | 2013-11-06 | 2013-11-08 | $158.75 | $1.7M | +0.0% | +0.0% | +0.0% |
| ACT | SELL | 2013-08-05 | 2013-08-13 | $136.25 | $1.1M | +0.0% | +0.0% | +0.0% |
| WPI | SELL | 2012-02-29 | 2012-03-01 | $58.80 | $293K | N/A | N/A | N/A |
| WPI | SELL | 2011-06-01 | 2011-06-01 | $64.45 | $170K | N/A | N/A | N/A |
| WPI | SELL | 2011-03-03 | 2011-03-04 | $56.36 | $423K | N/A | N/A | N/A |
| WPI | SELL | 2010-12-06 | 2010-12-07 | $51.00 | $186K | N/A | N/A | N/A |
| WPI | SELL | 2010-03-12 | 2010-03-16 | $40.85 | $1.2M | N/A | N/A | N/A |
| WPI | SELL | 2009-12-10 | 2009-12-11 | $38.25 | $727K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.